Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 25, Issue 12 I, 2005, Pages 1736-1745

  Kiser, Tyree H ^a   Jung, Rose ^a   MacLaren, Robert ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Anticoagulation; Bleeding; Dose; Enzyme linked immunosorbent assay; H PF4 ELISA; Heparin platelet factor 4; Platelet aggregation test; Serotonin release assay

Indexed keywords

ARGATROBAN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; LEPIRUDIN; THROMBIN INHIBITOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE RESPONSE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; UNIVERSITY HOSPITAL; UNNECESSARY PROCEDURE;

ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; PLATELET ACTIVATION; PLATELET AGGREGATION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 29044450662     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.12.1736     Document Type: Article

References (31)

1. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43.
2. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: heparin-associated thrombocytopenia study (HAT) investigators. Circulation 1999;100(6):587-93.
3. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99(1):73-80.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopcnia. N Engl J Med 2001;344(17): 1286-92.
5. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997;17(5):325-41.
6. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96(3):846-51.
7. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163(15):1849-56.
8. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):311S-37.
9. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20(3): 318-29.
10. McKeage K, Plosker GL. Argatroban. Drugs 2001;61(4): 515-24.
11. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24(3):409-14.
12. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 2002;28(5):467-82.
13. Chong BH. Heparin-induced thrombocytopcnia. Br J Haematol 1995;89(3):431-9.
14. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopcnia. Blood 2000;96(5):1703-8.
15. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2(2):148-57.
16. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002;126(11):1415-23.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
18. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003;37(7-8):970-5.
19. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111(5):700-6.
20. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99(19):2530-6.
21. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69(4):344-50.
22. Pfueller SL, David R. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol 1986;64(1):149-59.
23. Warkentin TE, Hayward CP, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120(3):371-9.
24. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000;10(suppl 1):35-45.
25. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110(2-3):73-82.
26. Stephens JL, Koerber JM, Mattson JC, Smythe MA. Effect of lepirudin on the international normalized ratio. Ann Pharmacother 2005;39(1):28-31.
27. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004;121(4):593-9.
28. Lubenow N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia [abstr]. Blood 2002; 100(suppl 1):502a.
29. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101(5):502-7.
30. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106(6): 629-35.
31. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5.